Lubricating Eye Drop

Phase 2Small molecule

Lubricating Eye Drop is one of 7 small molecule programs targeting Recurrent Ovarian Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Ovarian CancerActive, not recruiting

Recurrent Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Recurrent Ovarian Cancer

#DrugCompanyPhaseTrials

Elahere

IImmunogenics, LLC

Phase 2

1 2

Paraplatin

AAvyxa

Phase 1

1 3

Libtayo

Regeneron

Preclinical

1 4

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

1 5

Actemra

CCelltrion

Preclinical

1 6

Lubricating Eye Drop

AbbVie

Phase 2

1 7

Ubamatamab

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Recurrent Ovarian Cancer

NCT06365853

Clinical

Trials by Indication[1]

Acceptability1 trial

Efficacy and Acceptability of Two Lubricant Eye Drops

Completed· AbbVie logo

AbbVie·Phase 4·NCT00756678·51 enrolled

Ketorolac1 trial

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

Completed· AbbVie logo

AbbVie·Phase 4·NCT00791323·9 enrolled

Recurrent Ovarian Cancer1 trial

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT06365853·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Lubricating Eye Drop. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lubricating Eye Drop compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lubricating Eye Drop. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AbbVie

Lubricating Eye Drop

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Acceptability1 trial

Ketorolac1 trial

Recurrent Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News